Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release

ASKA Pharmaceutical Holdings Co., Ltd.

ASKA Obtains Manufacturing and Marketing Approval for LEUPRORELIN ACETATE SR FOR INJECTION KIT

TOKYO, August 15, 2025 – ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (TSE:4886), announced that ASKA has obtained the manufacturing and marketing approval for an LH-RH derivative microcapsule-type sustained-release agent, LEUPRORELIN ACETATE SR FOR INJECTION KIT (generic name: leuprorelin, hereinafter "the Product").

Based on the technology of NIPRO CORPORATION, the Product was co-developed by the two companies.

The Product will be used in the treatment of prostate cancer and premenopausal breast cancer. By promoting the use of generics in the fields of obstetrics and gynecology, and urology, which are ASKA's core therapeutic areas, ASKA believes that it can contribute to society.

Overview of LEUPRORELIN ACETATE SR FOR INJECTION KIT

Product name:	LEUPRORELIN ACETATE SR FOR INJECTION KIT
Generic name:	Leuprorelin acetate for injection
Indication:	- Prostate cancer - Premenopausal breast cancer
Dosage and Administration :	The usual adult dosage is 11.25 mg of leuprorelin acetate administered subcutaneously once every 12 weeks. To administer, push the plunger rod with the needle up and transfer the entire suspension solution to the powder section and suspend it thoroughly, taking care not to foam.

Media Contacts
ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp